Guillaume Grzych

Dr. Guillaume Grzych


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2019 in Current Opinion in Lipidology
Verified
Journal Article
Closed access
OCOscar Chávez-Talavera
Oscar Chávez-Talavera
JHJoel Haas
Joel Haas
GGGuillaume Grzych
Guillaume Grzych
ATAnne Tailleux
Anne Tailleux
BSBart Staels
Bart Staels
Purpose of review: The purpose of this review is to discuss the influence of obesity, insulin resistance, type 2 diabetes (T2D), and nonalcoholic fatty liver disease (NAFLD) on bile acid metabolism and to analyze whether these findings reinforce current beliefs about the role of bile acids in the pathophysiology of these diseases. Recent findings: Discordant results on plasma bile acid alterations in NAFLD patients have been reported. Obesity, insulin resistance, and T2D, common comorbidities of NAFLD, have been associated with bile acid changes, but the individual bile acid species variations differ between studies (summarized in this review), perhaps because of clinicobiological differences between the studied patient populations and the heterogeneity of statistical analyses applied. Summary: The regulatory role of bile acids in metabolic and cellular homeostasis renders bile acids attractive candidates as players in the pathophysiology of NAFLD. However, considering the complex relationship between NAFLD, obesity, insulin resistance and T2D, it is difficult to establish clear and independent associations between bile acid alterations and these individual diseases. Though bile acid alterations may not drive NAFLD progression, signaling pathways activated by bile acids remain potent therapeutic targets for its treatment. Further studies with appropriate matching or adjustment for potential confounding factors are necessary to determine which pathophysiological conditions drive the alterations in bile acid metabolism.

9 April 2020 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
GGGuillaume Grzych
Guillaume Grzych
LVLuisa Vonghia
Luisa Vonghia
MBMarie-Adélaïde Bout
Marie-Adélaïde Bout
JWJonas Weyler
Jonas Weyler
AVAn Verrijken
An Verrijken
BSBart Staels
Bart Staels
Context Plasma branched chain amino acid (BCAA) concentrations correlate positively with body mass index (BMI), measures of insulin resistance (IR) and severity of non-alcoholic fatty liver disease (NAFLD). Moreover, plasma BCAA concentrations also differ between the sexes, which display different susceptibilities to cardio-metabolic diseases. Objective Assess whether plasma BCAA concentrations associate with NAFLD severity independently of BMI, IR and sex. Patients Patients visiting the obesity clinic of the Antwerp University Hospital were consecutively recruited from 2006 to 2014. Design and Setting A cross-sectional study cohort of 112 obese patients (59 women and 53 men) was divided into four groups according to NAFLD severity. Groups were matched for sex, age, BMI, HOMA-IR and HbA1c. Main Outcome Measures Fasting plasma BCAA concentrations were measured by tandem mass spectrometry using the aTRAQ™ method. Results In the study cohort, a modest positive correlation was observed between plasma BCAA concentrations and NAFLD severity, as well as a strong effect of sex on plasma BCAA levels. Subgroup analysis by sex revealed that while plasma BCAA concentrations increased with severity of NAFLD in women, they tended to decrease in men. Additionally, only women displayed significantly increased plasma BCAAs with increasing fibrosis. Conclusion Plasma BCAA concentrations display sex-dimorphic changes with increasing severity of NAFLD, independently of BMI, IR and age. Additionally, plasma BCAA are associated with significant fibrosis in women, but not in men. These results highlight the importance of a careful consideration of sex as a major confounding factor in cross-sectional studies of NAFLD.

1 July 2020 in Journal of Laboratory and Precision Medicine
Verified
Journal Article
Open access
PDF file
AHAghilès Hamroun
Aghilès Hamroun
JPJean-David Pekar
Jean-David Pekar
ALArnaud Lionet
Arnaud Lionet
AGAmjad Ghulam
Amjad Ghulam
PMPatrice Maboudou
Patrice Maboudou
FGFrançois Glowacki
François Glowacki
Calcium is a central electrolyte involved in many physiological functions commonly measured in clinical practice. Abnormal calcium levels are frequently found, and could have serious clinical consequences. The free form of calcium, also called ionized calcium, plays a determining role in the human body. Its measurement still remains limited by technical, analytical and financial constraints. To overcome these limits, many formulas have been developed to estimate the ionized calcium value. These formulas use blood parameters more easily measurable (total calcium, albumin, and proteins). Although these equations have always been questioned in the scientific literature, their use remains extremely common in clinical practice. Indeed, by their practical aspect, the usefulness of such equations is indisputable in many situations of the clinician daily practice. Conversely, some evidence has more recently pushed to the routine use of the ionized calcium dosage, to the point of potentially switching into a drift of inappropriate over-prescription. The aim of this article is first to describe the application of ionized calcium in clinical practice and to discuss about its measurement and estimation in laboratories.

17 December 2015 in Haematologica
Verified
Journal Article
Open access
PDF file
Nicolas DuployezNicolas Duployez
Nicolas Duployez
GGGuillaume Grzych
Guillaume Grzych
BDBenoît Ducourneau
Benoît Ducourneau
MFMartin Alarcon Fuentes
Martin Alarcon Fuentes
NGNathalie Grardel
Nathalie Grardel
CPClaude Preudhomme
Claude Preudhomme
Publisher's Disclaimer. E-publishing ahead of print is increasingly important for the rapid dissemination of science. Haematologica is, therefore, E-publishing PDF files of an early version of manuscripts that have completed a regular peer review and have been accepted for publication. E

28 November 2023 in Toxics
Verified
Journal Article
Open access
PDF file
EGEmeline Gernez
Emeline Gernez
GLGraham Lee
Graham Lee
JNJean-Paul Niguet
Jean-Paul Niguet
FZFarid Zerimech
Farid Zerimech
ABAnas Bennis
Anas Bennis
GGGuillaume Grzych
Guillaume Grzych
The recreational use of nitrous oxide (N2O), also called laughing gas, has increased significantly in recent years. In 2022, the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) recognized it as one of the most prevalent psychoactive substances used in Europe. Chronic nitrous oxide (N2O) exposure can lead to various clinical manifestations. The most frequent symptoms are neurological (sensitive or motor disorders), but there are also other manifestations like psychiatric manifestations or cardiovascular disorders (thrombosis events). N2O also affects various neurotransmitter systems, leading to its anesthetic, analgesic, anxiolytic and antidepressant properties. N2O is very challenging to measure in biological matrices. Thus, in cases of N2O intoxication, indirect biomarkers such as vitamin B12, plasma homocysteine and plasma MMA should be explored for diagnosis and assessment. Others markers, like oxidative stress markers, could be promising but need to be further investigated.

24 January 2023 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
GGGuillaume Grzych
Guillaume Grzych
SDSylvie Deheul
Sylvie Deheul
EGEmeline Gernez
Emeline Gernez
JDJean-Baptiste Davion
Jean-Baptiste Davion
DDDries Dobbelaere
Dries Dobbelaere
CTCéline Tard
Céline Tard